US82024L1035 - Common Stock
SHATTUCK LABS INC
NASDAQ:STTK (5/17/2024, 7:00:01 PM)
After market: 7.915 0 (0%)7.915
+0.08 (+0.96%)
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 105 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. SL-172154 is in an ongoing Phase I clinical trial for the treatment of patients with ovarian cancer. The company is also evaluating SL-172154 in an ongoing Phase I clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia (AML), and higher-risk myelodysplastic syndromes (HR-MDS). The firm is also advancing a Gamma Delta T Cell Engager, GADLEN platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703
P: 15129004690
CEO: Taylor Schreiber
Employees: 105
Website: https://www.shattucklabs.com/
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients;...
STTK stock results show that Shattuck Labs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shattuck Labs (NASDAQ:STTK) just reported results for the first quarter of 2024...
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of...
Here you can normally see the latest stock twits on STTK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: